Evidence for a Single Gene Effect Causing Polycystic Ovaries and Male Pattern Baldness

1993 ◽  
Vol 48 (11) ◽  
pp. 753-755
Author(s):  
A. H. Carey ◽  
K. L. Chan ◽  
F. Short ◽  
D. White ◽  
R. Williamson ◽  
...  
1993 ◽  
Vol 38 (6) ◽  
pp. 653-658 ◽  
Author(s):  
A. H. Carey ◽  
K. L. Chan ◽  
F. Short ◽  
D. White ◽  
R. Williamson ◽  
...  

1999 ◽  
Vol 84 (1) ◽  
pp. 38-43 ◽  
Author(s):  
A. Govind ◽  
M. S. Obhrai ◽  
R. N. Clayton

The aim of this study was to obtain evidence for the genetic basis of polycystic ovaries (PCO) and premature male pattern baldness (PMPB) by screening first-degree relatives of women affected by polycystic ovary syndrome (PCOS). Because of the high prevalence of PCO in the general population, we also studied first-degree relatives of ten asymptomatic control volunteers of reproductive age. The probands were recruited prospectively from infertility and endocrine clinics, where they presented with various clinical symptoms of PCOS. Each had PCO, on transvaginal ultrasound scan. The families of 29 probands and 10 volunteers agreed to take part in the study. Clinical, ultrasound, and biochemical parameters were used to define PCO/PCOS. All female relatives had an ovarian ultrasound scan and hormone profile performed. History was used to assign status in postmenopausal women. All male relatives were assessed for early onset (<30 yr old) male pattern baldness, by photographs. All relatives were assigned affected (PCO/PMPB) or nonaffected status, and segregation analysis was performed. Of the relatives of 29 PCOS probands, 15 of 29 mothers (52%), 6 of 28 fathers (21%), 35 of 53 sisters (66%), and 4 of 18 brothers (22%) were assigned affected status. First-degree female relatives of affected individuals had a 61% chance of being affected. Of the first-degree male relatives, 22% were affected. Of a total of 71 siblings of PCOS probands, 39 were affected, giving a segregation ratio of 39/32 (55%), which is consistent with autosomal dominant inheritance for PCO/PMPB. In the control families, 1 of 10 probands (10%), 1 of 10 mothers (10%), no fathers, 2 of 13 sisters (15%), and 1 of 11 brothers (9%) were affected. Of a total of 24 siblings, 3 were affected (13%), giving a segregation ratio (observed/expected) of 3/12, which was significantly different from autosomal dominant inheritance. The inheritance of PCO and PMPB is consistent with an autosomal dominant inheritance pattern in PCOS families, perhaps caused by the same gene. There was no such genetic influence in families of women without PCOS. Sisters of PCOS probands with polycystic ovarian morphology were more likely to have menstrual irregularity and had larger ovaries and higher serum androstenedione and dehydroepiandrosterone-sulfate levels than sisters without PCO. This suggests a spectrum of clinical phenotype in PCOS families. Men with PMPB had higher serum testosterone than those without. Collectively, these data are consistent with a role for genetic differences in androgen synthesis, metabolism, or action in the pathogenesis of PCOS.


1994 ◽  
Vol 3 (10) ◽  
pp. 1873-1876 ◽  
Author(s):  
Adam H. Carey ◽  
Dawn Waterworth ◽  
Kirty Patel ◽  
Davinia White ◽  
Julie Little ◽  
...  

2020 ◽  
pp. 7-24
Author(s):  
Eugene H. Cordes

Tracking down the metabolic basis of a remarkable human single-gene genetic disease provided the insight required to discover drugs to prevent prostate gland growth in aging men (benign prostatic hyperplasia, BPH) and prevent hair loss in men (male pattern baldness). Victims of this genetic disease are born with the appearance of females and are recognized as such. However, at puberty, they undergo a transformation and develop the characteristics of males. The underlying genetic defect is a mutation in the gene that codes for the enzyme 5-alpha reductase (5AR), which promotes conversion of testosterone (T) into the more potent male sex hormone dihydrotestosterone (DHT). Lack of sufficient DHT in utero prevents the full expression of male anatomy at birth, an issue that is corrected at the time of puberty when a surge of male sex hormones occurs. These men have a very small prostate gland that never grows, do not lose their hair, and do not get acne. This strongly suggests that DHT is the causative agent of BPH, male pattern baldness, and acne. An inhibitor of 5AR would create the functional equivalent of the genetic defect and would be expected to be effective in shrinking an enlarged prostate gland and slowing or preventing hair loss and acne in men. Finasteride is such an inhibitor and has met expectations. It is marketed as Proscar for BPH and Propecia for male pattern baldness. Finasteride is a teratogen (can cause birth defects) and has not been developed for acne for that reason.


1987 ◽  
Vol 14 (3) ◽  
pp. 469-475 ◽  
Author(s):  
Ernest K. Manders ◽  
Victor K. Au ◽  
Randolph K.M. Wong

Sign in / Sign up

Export Citation Format

Share Document